Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein Academic Article uri icon


MeSH Major

  • Cancer Vaccines
  • HLA-A Antigens
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Peptide Fragments
  • T-Lymphocytes
  • WT1 Proteins


  • Wilms tumor protein 1 (WT1) is a transcription factor overexpressed in several types of leukemia and solid tumors. For this reason, WT1 is an attractive target for immunotherapy. Four peptide nonamers from WT1 have been identified by others to generate a WT1-specific cytotoxic response in the context of human leukocyte antigen (HLA)-A0201 and A2402. However, as WT1 is a self-antigen, breaking tolerance is a potential obstacle to vaccination. Here, we use a strategy to circumvent tolerance by designing synthetic immunogenic analog peptides that could crossreact to the native peptides (a heteroclitic response). A number of synthetic peptides derived from nonamer sequences of the WT1 protein were designed in which single amino-acid substitutions were introduced at HLA-A0201 major histocompatibility complex (MHC)-binding positions. Several of new peptides could stabilize MHC class I A0201 molecules better than native sequences. Some analogs were also able to elicit WT1-specific T-cell recognition and cytotoxic T-cell lymphocytes more effectively than native sequences. Importantly, T cells stimulated with the new analogs crossreacted with the native WT1 peptide sequence and were able to kill HLA-matched chronic myeloid leukemia cell lines. In conclusion, analog heteroclitic WT1 peptides with increased immunogenicity can be synthesized and are potential cancer vaccine candidates.

publication date

  • November 2006



  • Academic Article



  • eng

Digital Object Identifier (DOI)

  • 10.1038/sj.leu.2404380

PubMed ID

  • 16990779

Additional Document Info

start page

  • 2025

end page

  • 33


  • 20


  • 11